All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Undisclosed
Partner/Sponsor/Collaborator: Exscientia
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 19, 2021
Details:
Exscientia will use its AI-driven technology to generate novel clinical assets targeting this pathway. This will build on years of research by the ARUK-ODDI, which has identified chemical starting points that modulate NLRP3 inflammasome formation.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Undisclosed
Partner/Sponsor/Collaborator: Sosei Heptares
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 01, 2021
Details:
The collaboration aims to demonstrate the potential of Sosei Heptares’ SBDD technologies to address disease-associated ion channels and work towards establishing a leadership position in this area, in a similar way that it has done for G protein-coupled receptors (GPCRs).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): saRNA therapies
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Large molecule
Partner/Sponsor/Collaborator: Servier
Deal Size: $262.2 million Upfront Cash: Undisclosed
Deal Type: Collaboration January 21, 2021
Details:
As part of the collaboration, MiNA Therapeutics will use its saRNA platform to identify new potential treatments to restore normal cell function in neurological disorders.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AAV-based gene therapy
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Biogen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 08, 2021
Details:
Under the terms of the agreement, CEVEC grants Biogen a non-exclusive license for CEVEC’s ELEVECTA® Technology. The deal will afford Biogen the rights to use the technology across their portfolio of gene therapy products.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Small molecule
Partner/Sponsor/Collaborator: Vertex Pharmaceuticals
Deal Size: $2,240.0 million Upfront Cash: $40.0 million
Deal Type: Collaboration December 22, 2020
Details:
The collaboration leverages SkySTAR™ platform to discover and develop novel small molecule therapeutics that modulate RNA splicing which have the potential to transform the lives of patients with serious diseases.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): tRNA-based gene therapies
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Zogenix
Deal Size: $115.0 million Upfront Cash: $10.0 million
Deal Type: Collaboration December 03, 2020
Details:
Under the collaboration, Tevard will utilize its two unique tRNA-based discovery platforms focused on mRNA Stabilization and Nonsense Codon Suppression to discover and advance novel drug candidates for the treatment of Dravet syndrome and other genetic epilepsies.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Small molecule
Partner/Sponsor/Collaborator: Eisai Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 30, 2020
Details:
The collaboration will use Wren’s network kinetics drug discovery platform, alongside Eisai’s extensive experience in drug discovery for neurodegenerative disorders, to accelerate the development of clinical candidates.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AAV vectors based gene therapies
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: $1,800.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration October 14, 2020
Details:
Dyno will design novel AAV capsids with improved functional properties for gene therapy, while Roche and Spark Therapeutics will be conducting preclinical, clinical and commercialization activities for gene therapy product candidates using the novel capsids.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): VYR-206
Therapeutic Area: Neurology Product Name: VYR-206
Highest Development Status: Discovery Platform Product Type: Small molecule
Partner/Sponsor/Collaborator: National Yang-Ming University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 05, 2020
Details:
The MOU expresses the intent to develop the bio-distribution information and targeting profile of VYR-206 for diagnosis and monitoring treatment outcomes of neurological disorders.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Small molecule
Partner/Sponsor/Collaborator: Cerevel Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 27, 2020
Details:
Cerevel will utilize Cyclica’s Ligand Express® and Ligand Design™ platforms to screen, identify, evaluate and optimize targets to develop neuroscience medicines.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
